Lipid‐based nanoparticles have emerged as a clinically viable platform technology to
deliver nucleic acids for a wide range of healthcare applications. Within this scope, one of …

In recent years, various nanotechnology platforms in the area of medical biology, including
both diagnostics and therapy, have gained remarkable attention. Moreover, research and …

The successful development of nonviral delivery systems for nucleic acids has been
reported extensively over the past number of years. Among them, lipid-based nanoparticles …

Lipid nanoparticles (LNPs) are the most versatile and successful gene delivery systems,
notably highlighted by their use in vaccines against COVID-19. LNPs have a well-defined …

Over the past decade, the therapeutic potential of nanomaterials as novel drug delivery
systems complementing conventional pharmacology has been widely acknowledged …

Lipid nanoparticles (LNPs) have emerged across the pharmaceutical industry as promising
vehicles to deliver a variety of therapeutics. Currently in the spotlight as vital components of …

Lipid-based drug-delivery systems have evolved from micro-to nano-scale, enhancing the
efficacy and therapeutic applications of these delivery systems. Production of lipid-based …

Lipid‐based nanoparticles (LBNPs) are currently the most promising vehicles for nucleic
acid drug (NAD) delivery. Although their clinical applications have achieved success, the …

Nucleic acid therapeutics hold an unprecedented promise toward treating many challenging
diseases; however, their use is hampered by delivery issues. Microfluidics, dealing with …

Lipid nanoparticles have attracted significant interests in the last two decades, and have
achieved tremendous clinical success since the first clinical approval of Doxil in 1995. At the …